ASHLEY STEINHAUER: Open Payments
NPI 1356624555 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,847 in 89 payments from 35 companies in 2025. Trend: 2023 $2,026 · 2024 $1,818 · 2025 $1,847
Food & beverage: $1,847
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $183 |
| Celgene Corporation | 9 | $170 |
| PFIZER INC. | 7 | $129 |
| ABBVIE INC. | 4 | $101 |
| Janssen Biotech, Inc. | 5 | $92 |
| AstraZeneca Pharmaceuticals LP | 4 | $87 |
| E.R. Squibb & Sons, L.L.C. | 4 | $87 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Alexion Pharmaceuticals, Inc. | 4 | $76 |
| ARRAY BIOPHARMA INC | 3 | $70 |
Products named: REBLOZYL, KISQALI, IBRANCE, ULTOMIRIS, TALVEY, OPDIVO, EPKINLY, Orserdu.
Industry payments across LA — which companies pay providers there.
